{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T13:30:15Z","timestamp":1794749415330,"version":"4.9.1"},"reference-count":23,"publisher":"Wiley","issue":"s5","license":[{"start":{"date-parts":[[2007,12,7]],"date-time":"2007-12-07T00:00:00Z","timestamp":1196985600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:p><jats:bold>Abstract\u2002<\/jats:bold> Two therapeutic approaches are available to manage patients with von Willebrand disease (VWD): (i) the release of endogenous von Willebrand factor (VWF) from endothelial compartments induced by desmopressin (DDAVP); (ii) the transfusion of exogenous VWF contained in VWF\/FVIII plasma\u2010derived concentrates. Only a few high\u2010purity VWF\/FVIII concentrates have been extensively evaluated in pharmacokinetic (PK) trials as well as in retrospective or prospective efficacy studies in VWD. The Alphanate Study Group published results of PK and clinical efficacy studies in 2002. Efficacy results showed that 75% of bleeding episodes were controlled with one or two infusions, and 71% of patients who received prophylactic treatment for surgeries or invasive procedures had good clinical responses. In another retrospective study, 22 VWD patients in Italy received Fanhdi, a VWF concentrate similar to Alphanate. Excellent\u2013good clinical responses were seen in 92% of bleeding episodes and in 93% of surgical procedures. More recently, the efficacy and safety of Fanhdi have been evaluated retrospectively in a larger cohort of Italian patients (<jats:italic>n<\/jats:italic>\u2003=\u2003103) with 97% (bleedings) and 99% (surgeries) of excellent\/good clinical responses. The largest experience on secondary prophylaxis in VWD has been collected in Sweden in 35 patients with severe forms of VWD. Secondary prophylaxis was also implemented in a cohort of Italian patients with VWD. Prophylaxis was started because of GI bleeds in seven patients with types 3 (<jats:italic>n<\/jats:italic>\u2003=\u20031), 2A (<jats:italic>n<\/jats:italic>\u2003=\u20034), 2M (<jats:italic>n<\/jats:italic>\u2003=\u20031) and type 1 (<jats:italic>n<\/jats:italic>\u2003=\u20031) and for joint bleeds in four patients with type 3 VWD (<jats:italic>n<\/jats:italic>\u2003=\u20034). Prophylaxis prevented bleeding completely in eight patients and largely reduced hospitalization for blood transfusions in the remaining three. The cost\u2010effectiveness of these prophylaxis regimens versus on demand therapy will be now investigated in one large prospective study (PRO.WILL) organized in Italy.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2007.01573.x","type":"journal-article","created":{"date-parts":[[2010,9,15]],"date-time":"2010-09-15T13:14:22Z","timestamp":1284556462000},"page":"15-24","source":"Crossref","is-referenced-by-count":33,"title":["Highly purified VWF\/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO.WILL Study"],"prefix":"10.1111","volume":"13","author":[{"given":"A. B.","family":"FEDERICI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,12,7]]},"reference":[{"key":"e_1_2_3_2_2","first-page":"94","article-title":"Von Willebrand\u2019s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman G","year":"2003","journal-title":"Haematologica"},{"issue":"2","key":"e_1_2_3_3_2","first-page":"1","article-title":"Proceedings of a Nordic von Willebrand symposium","volume":"5","author":"Lee CA","year":"1999","journal-title":"Haemophilia"},{"key":"e_1_2_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01393.x"},{"key":"e_1_2_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02146.x"},{"key":"e_1_2_3_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00672.x"},{"key":"e_1_2_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00991.x"},{"key":"e_1_2_3_8_2","first-page":"1","article-title":"von Willebrand\u2019s disease in Sweden","volume":"238","author":"Silwer J","year":"1973","journal-title":"Acta Paediatr Scand"},{"key":"e_1_2_3_9_2","first-page":"1223","article-title":"Clinical manifestations and complications of childbirth and replacement therapy in 348 Iranian patients with type 3 von Willebrand disease","volume":"111","author":"Lak M","year":"2000","journal-title":"Br J Haematol"},{"key":"e_1_2_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01663.x"},{"key":"e_1_2_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01847.x"},{"key":"e_1_2_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040403"},{"key":"e_1_2_3_13_2","first-page":"363","article-title":"The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, ATIII and OT in man","volume":"27","author":"Cash JD","year":"1974","journal-title":"Br J Haematol"},{"key":"e_1_2_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041540307"},{"key":"e_1_2_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91197-7"},{"key":"e_1_2_3_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2072"},{"key":"e_1_2_3_17_2","volume-title":"Guideline on the Clinical Investigation of Human Plasma Derived Von Willebrand Factor Products (CPMP\/BPWG\/220\/02)","author":"From the CHMP","year":"2005"},{"key":"e_1_2_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167658.85143.49"},{"key":"e_1_2_3_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.2.450"},{"key":"e_1_2_3_20_2","volume-title":"Product Approval Information \u2013 Licensing Action","author":"From the FDA","year":"2007"},{"key":"e_1_2_3_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00688.x"},{"key":"e_1_2_3_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613225"},{"key":"e_1_2_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167659.23262.18"},{"key":"e_1_2_3_24_2","doi-asserted-by":"crossref","first-page":"507a","DOI":"10.1182\/blood.V106.11.1782.1782","article-title":"Secondary long\u2010term prophylaxis in severe patients with von Willebrand disease: an Italian cohort study","volume":"106","author":"Federici AB","year":"2005","journal-title":"Blood"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2007.01573.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2007.01573.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T07:19:04Z","timestamp":1695712744000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2007.01573.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":23,"journal-issue":{"issue":"s5","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1111\/j.1365-2516.2007.01573.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01573.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}